Tern Therapeutics is partnering with Andelyn Biosciences to develop its investigational gene therapy that targets vision loss…
Articles by Andrea Lobo, PhD
Gene therapy targeting nerve cells in the gut improved nerve cell survival and intestinal function — specifically that of the…
Treatment with the investigational therapy Batten-1 (miglustat) for 18 months, or about 1.5 years, stabilized motor symptoms in patients with…
Theranexus has launched a global offering of around €4 million (about $4.5 million) to help fund the pivotal Phase…
Treatment for up to six months with Batten-1 — Theranexus’ novel therapy for juvenile Batten disease — reduced…